跳转至内容
Merck
CN
  • ¹⁸F-FDG-PET/CT Imaging in Patients with Febrile Neutropenia and Haematological Malignancies.

¹⁸F-FDG-PET/CT Imaging in Patients with Febrile Neutropenia and Haematological Malignancies.

Anticancer research (2015-05-13)
Vincent Camus, Agathe Edet-Sanson, Michael Bubenheim, Anne Hitzel, Stéphanie Becker, Marion David, Aspasia Stamatoullas, Pascal Lenain, Fabrice Jardin, Nathalie Contentin, Marie Laure Fontoura, Nathalie Cardinael, Sandrine Vaudaux, Sydney Dubois, Hervé Tilly, Pierre Vera, Stéphane Leprêtre
摘要

The aim of the present study was to assess the prevalence of hyper-metabolic infection sites revealed by fluorine-18 ((18)F) fluorodeoxyglucose (FDG) positron-emission tomography (PET) combined with computed tomography (CT) in patients with febrile neutropenia (FN). Forty-eight consecutive patients with haematological malignancies and persistent FN (temperature ≥ 38°C and neutrophil count <500 cells/μl for more than two days) as a consequence of intensive chemotherapy were prospectively included. Pathological FDG uptakes identified 31 foci of infections located in the lungs (n=15, 48.4 %), colon (n=4, 12.9%), pancreas (n=2, 6.5%), skin (n=3, 9.7%), ear-nose-throat area (n=5, 16.1%), central venous catheter tract (n=1, 3.2%) and gallbladder (n=1, 3.2%). These pathological FDG uptakes were observed in half of the 48 patients (n=24). Among the 38 patients with a clinical diagnosis of infection, 23 showed a pathological FDG uptake, resulting in a FDG-PET/CT sensitivity of 61% (95% CI, 43-76%). Our study confirmed the ability of FDG-PET/CT to diagnose infections in patients with persistent FN.

材料
产品编号
品牌
产品描述

Sigma-Aldrich
乙醇钽(V), 99.98% trace metals basis
Sigma-Aldrich
荧光素二(β-D-吡喃半乳糖苷)
乙醇钽(V), packaged for use in deposition systems